Your browser doesn't support javascript.
loading
Changes in the tumor immune microenvironment in resected recurrent soft tissue sarcomas.
Zheng, Biqiang; Wang, Jian; Cai, Weiluo; Lao, Iweng; Shi, Yingqiang; Luo, Xiaoying; Yan, Wangjun.
Afiliação
  • Zheng B; Department of Musculoskeletal Cancer Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
  • Wang J; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
  • Cai W; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
  • Lao I; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
  • Shi Y; Department of Musculoskeletal Cancer Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
  • Luo X; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
  • Yan W; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Ann Transl Med ; 7(16): 387, 2019 Aug.
Article em En | MEDLINE | ID: mdl-31555701
ABSTRACT

BACKGROUND:

Little is known about how the tumor immune microenvironment (TIME) is modulated in recurrent soft tissue sarcomas (STS).

METHODS:

We evaluated CD8+ T cells, CD20+ B cells, Foxp3+ regulatory T cells (Tregs), and programmed cell death ligand 1 (PD-L1) in 72 paired pre-recurrent (1st resected) versus post-recurrent (2nd resected) STS by immunohistochemistry. Correlations with time to recurrence and prognosis were determined.

RESULTS:

We found that CD8, PD-L1, CD20, and Foxp3-positive cell counts changed in post-recurrent STS. PD-L1-positive tumor cell and lymphocyte counts increased in post-recurrent STS, whereas CD8+ T cell counts decreased. Changes in CD8+ T cell, CD20+ B cell, and PD-L1+ lymphocyte counts were associated with the time interval between surgeries. At admission, fewer CD8+ T cells were detected in patients with relapse than in newly diagnosed patients. Furthermore, post-recurrent STS with fewer CD8+ T cells compared with pre-recurrent STS were more likely to exhibit re-recurrence. The change in CD8+ T cells was positively associated with overall survival. In multivariate analyses, a decrease in CD8+ T cell counts in post-recurrent STS was an independent unfavorable prognostic factor.

CONCLUSIONS:

The TIME differs between pre-recurrent STS and post-recurrent STS. The variation in CD8+ T cells and PD-L1 positivity may have essential roles during tumor relapse and provides a basis for determining therapeutic strategies.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article